title: [Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies].
abstract: The newly developed sustained-release form of isradipine (Vascal uno/Lomir SRO) releases the active substance continuously from a gel matrix over a period of 24 hours. In comparison with the standard formulation, the absolute bioavailability of the sustained-release preparation is somewhat increased at about 22.5%. Maximum plasma levels are reached five to seven hours after oral administration of a capsule, and then level off. Both maximum plasma levels and bioavailability increase linearly with dose. At therapeutic dosage isradipine does not accumulate. Twenty-four hours after ingestion of the capsule, plasma levels are still half the maximum. As a result of slow absorption and minimal fluctuations in the concentration of the active agent, side effects of the sustained-release version of isradipine are even rarer than with the standard preparation.
authors.affiliation: Schwarz Pharma AG, Monheim.
authors.forename: R
authors.initials: R
authors.lastname: Hirschberger
mesh_terms: D001682:Biological Availability; D003692:Delayed-Action Preparations; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D017275:Isradipine / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate / Q000502:physiology
chemical_list: D003692:Delayed-Action Preparations; D017275:Isradipine
vernacular_title: Pharmakokinetik und -dynamik der Retardformulierung von Isradipin. Zusammenfassung der bisher vorliegenden Studien.